Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

B2635

Supelco

1,4-Butandiol-dimethansulfonat

analytical standard, for drug analysis

Synonym(e):

Busulfan

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Lineare Formel:
CH3SO2O(CH2)4OSO2CH3
CAS-Nummer:
55-98-1
Molekulargewicht:
246.30
Beilstein:
1791786
EG-Nummer:
200-250-2
MDL-Nummer:
MFCD00007562
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329773205
NACRES:
NA.24

Qualität

analytical standard, for drug analysis

Qualitätsniveau

100

Methode(n)

HPLC: suitable
gas chromatography (GC): suitable

mp (Schmelzpunkt)

114-117 °C (lit.)

Anwendung(en)

forensics and toxicology
veterinary

Format

neat

SMILES String

CS(=O)(=O)OCCCCOS(C)(=O)=O

InChI

1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3

InChIKey

COVZYZSDYWQREU-UHFFFAOYSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Allgemeine Beschreibung

Busulfan is a bifunctional alkylating agent, which may find application in the treatment of chronic granulocytic leukemia.

Anwendung

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Piktogramme

Skull and crossbonesHealth hazard
GHS06,GHS08

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Oral - Carc. 1A - Muta. 1B - Repr. 1B

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number
WXBF3873V
BCCK8828
BCCG5556
BCCF4469
BCCC6140

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 5

1 of 5

vibrant-m

Y0001457

Melphalan für die Systemeignung

Cyclophosphamid British Pharmacopoeia (BP) Reference Standard

BP1094

Cyclophosphamid

Ifosfamid ≥98%

Sigma-Aldrich

I4909

Ifosfamid

Cyclophosphamide Monohydrate A widely used anti-neoplastic agent that also displays immunosuppressant properties.

Sigma-Aldrich

239785

Cyclophosphamide Monohydrate

Poly(ethylenglykol) average mol wt 400

Sigma-Aldrich

P3265

Poly(ethylenglykol)

Blood and Marrow Stem Cell Transplantation: Principles, Practice, and Nursing Insights (1997)
Arnon Nagler et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(28), 3549-3556 (2013-08-28)
Cyclophosphamide (Cy) combined with total-body irradiation (TBI) or with busulfan (Bu) are currently the most common myeloablative regimens used in allogeneic stem-cell transplantation (alloSCT) in adults with acute myelogenous leukemia (AML). Intravenous (IV) Bu has more predictable bioavailability and a
Yan Zhao et al.
Stem cell research & therapy, 11(1), 466-466 (2020-11-06)
Premature ovarian insufficiency (POI) is an ovarian dysfunction that seriously affects a woman's physiological health and reproduction. Mesenchymal stem cell (MSC) transplantation offers a promising treatment option for ovarian restoration in rodent POI models. However, the efficacy and mechanism of
Edward A Copelan et al.
Blood, 122(24), 3863-3870 (2013-09-26)
Cyclophosphamide combined with total body irradiation (Cy/TBI) or busulfan (BuCy) are the most widely used myeloablative conditioning regimens for allotransplants. Recent data regarding their comparative effectiveness are lacking. We analyzed data from the Center for International Blood and Marrow Transplant
Christopher Bredeson et al.
Blood, 122(24), 3871-3878 (2013-10-02)
We conducted a prospective cohort study testing the noninferiority of survival of ablative intravenous busulfan (IV-BU) vs ablative total body irradiation (TBI)-based regimens in myeloid malignancies. A total of 1483 patients undergoing transplantation for myeloid malignancies (IV-BU, N = 1025;
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.